Remove Confidentiality Remove Licensing Remove Marketing Remove Settlement
article thumbnail

Formycon/Fresenius Kabi and Samsung Bioepis Settlements with J&J and Janssen Biotech regarding Ustekinumab

LexBlog IP

On August 7, 2023, Formycon AG and Fresenius Kabi announced that they have reached a settlement with Johnson & Johnson (“J&J”) in the United States relating to FYB202, a proposed ustekinumab biosimilar to STELARA®, marketed by J&J. Economic terms of the settlement were not disclosed in the press release.

article thumbnail

Celltrion Stelara (Ustekinumab) Settlement With J&J

LexBlog IP

It has been reported that Celltrion has finalized a settlement with Johnson & Johnson (“J&J”) in the United States relating to CT-P43, Celltrion’s ustekinumab biosimilar to J&J’s STELARA®, which would permit Celltrion to launch the product in the U.S. market on March 7, 2025, if approved by FDA.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Fish & Richardson Obtains Settlement and License Agreement for Skull Shaver in Patent Infringement Dispute with Magicfly

Fish & Richardson Trademark & Copyright Thoughts

Fish & Richardson obtained a settlement and license agreement for Skull Shaver, LLC, the market leader in uniquely designed and patented handheld electric shavers and personal grooming products, in a patent infringement lawsuit against Magicfly LLC.

article thumbnail

Fresenius Kabi Announces FDA Approval of TYENNE, a Tocilizumab Biosimilar Referencing ACTEMRA

LexBlog IP

at a future date “[i]n accordance with [Fresenius Kabi’s] patent settlement agreement with Genentech” under which Fresenius Kabi has a license to market its tocilizumab products in the U.S. starting at confidential license dates. TYENNE will be available in the U.S.

article thumbnail

Daniel Alexander KC says "no" on indemnity costs, blanket confidentiality orders and permission to appeal in Oxford University Innovation dispute

The IPKat

In the consequentials hearing judgment [2023] EWHC 138 , the Judge dealt with (1) royalty payments; (2) costs; (3) confidentiality; and (4) permission to appeal. Of the most interesting to this Kat was the treatment of costs (well, some of them), confidentiality and permission to appeal.

article thumbnail

Biosimilar Maker Leverages IPR to Avoid Patent Dance and Obtain Early Market Entry

Bio Law Blog

settled three Inter Partes Review (IPR) proceedings concerning patents covering Alexion’s blockbuster humanized monoclonal antibody drug Soliris®, with Amgen obtaining a royalty-free license for marketing a biosimilar prior to expiration of the patents at issue. and Alexion Pharmaceuticals Inc. an eculizumab product.

article thumbnail

Hollywood Wins Injunction To Shut Down Pirate IPTV Operations, Disable Domain Names

TorrentFreak

A pending settlement agreement included a clause that Tusa couldn’t launch or be involved with any similar services. After the apparent demise of Area 51 but in advance of the settlement being finalized, it’s alleged that Tusa launched a close copy of Area 51 called SingularityMedia, which scooped up Area 51’s customers.